Future Research Directions in Multiple Sclerosis Therapies

 

 Buy Article Permissions and Reprints

ABSTRACT

The success of presently available injectable immunomodulatory therapies in treating multiple sclerosis has led to heightened interest in finding even more efficacious and better tolerated therapies. Several oral agents have shown efficacy in phase-II clinical trials and are now entering phase-III pivotal trials. In addition, monoclonal antibodies targeting surface receptors on various cells of the peripheral immune system have also shown efficacy in early studies and will soon be entering phase III. All of these approaches target immune molecules that are not specific for multiple sclerosis (MS) and carry inherent risk of infection and systemic side effects. Novel immunotherapies in preclinical or phases I to IIa testing are attempting to more selectively target pathogenic effector cells and thereby block abnormal immune cell activation without compromising normal healthy immune responses. The induction of tolerance to self-proteins continues to be a goal of MS immunotherapy, but as yet has not been accomplished outside of the laboratory. There is increasing awareness of the need to understand and modulate nonclassical immune targets as well as central nervous system degenerative processes. The roles of vitamins, antimicrobials, and hormones continue to be studied. The mechanisms of neurodegeneration in MS are likely multifactorial and include direct damage by T cells and humoral immunity as well as oxidative stress, glutamate-mediated excitotoxicity, and neuronal and oligodendrocyte apoptosis. Neuroprotective drugs that were once only considered for classical degenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease, are now being considered in MS.

REFERENCES

• 1 Pittock S J, Lucchinetti C F. The pathology of MS: new insights and potential clinical applications.  Neurologist. 2007;  13(2) 45-56
  CrossrefPubMedGoogle Scholar
• 2 Kleinschnitz C, Meuth S G, Kieseier B C, Wiendl H. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.  Endocr Metab Immune Disord Drug Targets. 2007;  7(1) 35-63
  PubMedGoogle Scholar
• 3 Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis.  Expert Rev Neurother. 2007;  7(3) 227-239
  CrossrefPubMedGoogle Scholar
• 4 Wolinsky J S. The use of glatiramer acetate in the treatment of multiple sclerosis.  Adv Neurol. 2006;  98 273-292
  PubMedGoogle Scholar
• 5 Wingerchuk D M. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.  Expert Rev Neurother. 2006;  6(3) 333-346
  CrossrefPubMedGoogle Scholar
• 6 Polman C H, O'Connor P W, Havrdova E et al.. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.  N Engl J Med. 2006;  354(9) 899-910
  CrossrefPubMedGoogle Scholar
• 7 Berger J R. Natalizumab.  Drugs Today (Barc). 2006;  42(10) 639-655
  CrossrefPubMedGoogle Scholar
• 8 O'Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.  Expert Opin Biol Ther. 2007;  7(1) 123-136
  CrossrefPubMedGoogle Scholar
• 9 Ransohoff R M. Natalizumab and PML.  Nat Neurosci. 2005;  8(10) 1275
  CrossrefPubMedGoogle Scholar
• 10 Martini S, Peters H, Bohler T, Budde K. Current perspectives on FTY720.  Expert Opin Investig Drugs. 2007;  16(4) 505-518
  CrossrefPubMedGoogle Scholar
• 11 Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.  Expert Opin Investig Drugs. 2007;  16(3) 283-289
  CrossrefPubMedGoogle Scholar
• 12 Kappos L, Antel J, Comi G et al.. Oral fingolimod (FTY720) for relapsing multiple sclerosis.  N Engl J Med. 2006;  355(11) 1124-1140
  CrossrefPubMedGoogle Scholar
• 13 Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.  Clin Exp Immunol. 2006;  145(1) 101-107
  CrossrefPubMedGoogle Scholar
• 14 Shear N H. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?.  Drug Saf. 2006;  29(1) 49-66
  CrossrefPubMedGoogle Scholar
• 15 Schimrigk S, Brune N, Hellwig K et al.. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.  Eur J Neurol. 2006;  13(6) 604-610
  CrossrefPubMedGoogle Scholar
• 16 Jonsson S, Andersson G, Fex T et al.. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.  J Med Chem. 2004;  47(8) 2075-2088
  CrossrefPubMedGoogle Scholar
• 17 Runstrom A, Leanderson T, Ohlsson L, Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.  J Neuroimmunol. 2006;  173(1-2) 69-78
  CrossrefPubMedGoogle Scholar
• 18 Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.  Neurology. 2005;  64(6) 987-991
  CrossrefPubMedGoogle Scholar
• 19 Zeyda M, Poglitsch M, Geyeregger R et al.. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.  Arthritis Rheum. 2005;  52(9) 2730-2739
  CrossrefPubMedGoogle Scholar
• 20 O'Connor P W, Li D, Freedman M S et al.. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.  Neurology. 2006;  66(6) 894-900
  CrossrefPubMedGoogle Scholar
• 21 Youssef S, Stuve O, Patarroyo J C et al.. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.  Nature. 2002;  420(6911) 78-84
  CrossrefPubMedGoogle Scholar
• 22 Vollmer T, Key L, Durkalski V et al.. Oral simvastatin treatment in relapsing-remitting multiple sclerosis.  Lancet. 2004;  363(9421) 1607-1608
  CrossrefPubMedGoogle Scholar
• 23 Giuliani F, Hader W, Yong V W. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction.  J Leukoc Biol. 2005;  78(1) 135-143
  CrossrefPubMedGoogle Scholar
• 24 Metz L M, Zhang Y, Yeung M et al.. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.  Ann Neurol. 2004;  55(5) 756
  CrossrefPubMedGoogle Scholar
• 25 Miron V E, Rajasekharan S, Jarjour A A, Zamvil S S, Kennedy T E, Antel J P. Simvastatin regulates oligodendroglial process dynamics and survival.  Glia. 2007;  55(2) 130-143
  CrossrefPubMedGoogle Scholar
• 26 Yang L, Sugama S, Chirichigno J W et al.. Minocycline enhances MPTP toxicity to dopaminergic neurons.  J Neurosci Res. 2003;  74(2) 278-285
  CrossrefPubMedGoogle Scholar
• 27 Munger K L, Levin L I, Hollis B W, Howard N S, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.  JAMA. 2006;  296(23) 2832-2838
  CrossrefPubMedGoogle Scholar
• 28 Spach K M, Nashold F E, Dittel B N, Hayes C E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.  J Immunol. 2006;  177(9) 6030-6037
  PubMedGoogle Scholar
• 29 van der Mei I A, Ponsonby A L, Dwyer T et al.. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia.  J Neurol. 2007;  254 581-590
  CrossrefPubMedGoogle Scholar
• 30 Voskuhl R R, Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.  Neuroscientist. 2001;  7(3) 258-270
  PubMedGoogle Scholar
• 31 Cree B. Emerging monoclonal antibody therapies for multiple sclerosis.  Neurologist. 2006;  12(4) 171-178
  CrossrefPubMedGoogle Scholar
• 32 Rastetter W, Molina A, White C A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.  Annu Rev Med. 2004;  55 477-503
  CrossrefPubMedGoogle Scholar
• 33 Cross A H, Stark J L, Lauber J, Ramsbottom M J, Lyons J A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.  J Neuroimmunol. 2006;  180(1-2) 63-70
  CrossrefPubMedGoogle Scholar
• 34 Stuve O, Cepok S, Elias B et al.. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.  Arch Neurol. 2005;  62(10) 1620-1623
  CrossrefPubMedGoogle Scholar
• 35 Waldmann T A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.  J Clin Immunol. 2007;  27(1) 1-18
  CrossrefPubMedGoogle Scholar
• 36 Rose J W, Watt H E, White A T, Carlson N G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.  Ann Neurol. 2004;  56(6) 864-867
  CrossrefPubMedGoogle Scholar
• 37 Bielekova B, Richert N, Howard T et al.. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.  Proc Natl Acad Sci USA. 2004;  101(23) 8705-8708
  CrossrefPubMedGoogle Scholar
• 38 Bielekova B, Catalfamo M, Reichert-Scrivner S et al.. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.  Proc Natl Acad Sci USA. 2006;  103(15) 5941-5946
  CrossrefPubMedGoogle Scholar
• 39 Coles A J, Cox A, Le Page E et al.. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.  J Neurol. 2006;  253(1) 98-108
  CrossrefPubMedGoogle Scholar
• 40 Loh Y, Oyama Y, Statkute L et al.. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.  Blood. 2007;  109(6) 2643-548
  CrossrefPubMedGoogle Scholar
• 41 Chong B F, Wong H K. Immunobiologics in the treatment of psoriasis.  Clin Immunol. 2007;  123(2) 129-138
  CrossrefPubMedGoogle Scholar
• 42 Gran B, Zhang G X, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination.  Crit Rev Immunol. 2004;  24(2) 111-128
  CrossrefPubMedGoogle Scholar
• 43 Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis.  Int Rev Immunol. 2005;  24(5-6) 393-413
  PubMedGoogle Scholar
• 44 Bielekova B, Goodwin B, Richert N et al.. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.  Nat Med. 2000;  6(10) 1167-1175
  CrossrefPubMedGoogle Scholar
• 45 Kappos L, Comi G, Panitch H et al.. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial.  The Altered Peptide Ligand in Relapsing MS Study Group . Nat Med. 2000;  6(10) 1176-1182
  PubMedGoogle Scholar
• 46 Smith C E, Miller S D. Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.  J Autoimmun. 2006;  27(4) 218-231
  CrossrefPubMedGoogle Scholar
• 47 Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.  Int Rev Immunol. 2005;  24(5-6) 415-446
  PubMedGoogle Scholar
• 48 Ishikawa H, Ochi H, Chen M L, Frenkel D, Maron R, Weiner H L. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.  Diabetes. 2007;  56 2103-2109
  CrossrefPubMedGoogle Scholar
• 49 Lovett-Racke A E, Rocchini A E, Choy J et al.. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.  Immunity. 2004;  21(5) 719-731
  CrossrefPubMedGoogle Scholar
• 50 Ivanov I I, McKenzie B S, Zhou L et al.. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells.  Cell. 2006;  126(6) 1121-1133
  CrossrefPubMedGoogle Scholar
• 51 Rus H, Pardo C A, Hu L et al.. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.  Proc Natl Acad Sci USA. 2005;  102(31) 11094-11099
  CrossrefPubMedGoogle Scholar
• 52 Beeton C, Pennington M W, Wulff H et al.. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.  Mol Pharmacol. 2005;  67 1369-1381
  CrossrefPubMedGoogle Scholar
• 53 Wulff H, Calabresi P A, Allie R et al.. Myelin-reactive effector memory T cell K + channels: a target for multiple sclerosis therapy.  J Clin Invest. 2003;  111 1703-1713
  CrossrefPubMedGoogle Scholar
• 54 Whartenby K A, Calabresi P A, McCadden E et al.. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.  Proc Natl Acad Sci USA. 2005;  102(46) 16741-16746
  CrossrefPubMedGoogle Scholar
• 55 Miller S D, McMahon E J, Schreiner B, Bailey S L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis.  Ann N Y Acad Sci. 2007;  1103 179-191
  CrossrefPubMedGoogle Scholar
• 56 Manuel S L, Rahman S, Wigdahl B, Khan Z K, Jain P. Dendritic cells in autoimmune diseases and neuroinflammatory disorders.  Front Biosci. 2007;  12 4315-4335
  CrossrefPubMedGoogle Scholar
• 57 Khoury S J, Gallon L, Verburg R R et al.. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat.  J Immunol. 1996;  157(8) 3700-3705
  PubMedGoogle Scholar
• 58 Makhlouf K, Comabella M, Imitola J, Weiner H L, Khoury S J. Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis.  J Neuroimmunol. 2001;  117(1-2) 156-165
  CrossrefPubMedGoogle Scholar
• 59 Bjartmar C, Trapp B D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences.  Curr Opin Neurol. 2001;  14(3) 271-278
  CrossrefPubMedGoogle Scholar
• 60 McQualter J L, Bernard C C. Multiple sclerosis: a battle between destruction and repair.  J Neurochem. 2007;  100(2) 295-306
  CrossrefPubMedGoogle Scholar
• 61 Hauser S L, Oksenberg J R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.  Neuron. 2006;  52(1) 61-76
  CrossrefPubMedGoogle Scholar
• 62 Maier K, Merkler D, Gerber J et al.. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation.  Neurobiol Dis. 2007;  25(3) 514-525
  CrossrefPubMedGoogle Scholar
• 63 Montero M, Poulsen F R, Noraberg J et al.. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures.  Exp Neurol. 2007;  204(1) 106-117
  CrossrefPubMedGoogle Scholar
• 64 King C E, Rodger J, Bartlett C, Esmaili T, Dunlop S A, Beazley L D. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection.  Exp Neurol. 2007;  205(1) 48-55
  CrossrefPubMedGoogle Scholar
• 65 Mi S, Miller R H, Lee X et al.. LINGO-1 negatively regulates myelination by oligodendrocytes.  Nat Neurosci. 2005;  8(6) 745-751
  CrossrefPubMedGoogle Scholar
• 66 Craner M J, Damarjian T G, Liu S et al.. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.  Glia. 2005;  49(2) 220-229
  CrossrefPubMedGoogle Scholar
• 67 Bechtold D A, Miller S J, Dawson A C et al.. Axonal protection achieved in a model of multiple sclerosis using lamotrigine.  J Neurol. 2006;  253(12) 1542-1551
  PubMedGoogle Scholar
• 68 Lo A C, Saab C Y, Black J A, Waxman S G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo.  J Neurophysiol. 2003;  90(5) 3566-3571
  CrossrefPubMedGoogle Scholar
• 69 Offner H, Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis.  Ann N Y Acad Sci. 2006;  1089 343-372
  CrossrefPubMedGoogle Scholar
• 70 Morales L B, Loo K K, Liu H B, Peterson C, Tiwari-Woodruff S, Voskuhl R R. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis.  J Neurosci. 2006;  26(25) 6823-6833
  CrossrefPubMedGoogle Scholar
• 71 Sicotte N L, Voskuhl R R. Onset of multiple sclerosis associated with anti-TNF therapy.  Neurology. 2001;  57(10) 1885-1888
  PubMedGoogle Scholar
• 72 Kumar S. Memantine: pharmacological properties and clinical uses.  Neurol India. 2004;  52(3) 307-309
  PubMedGoogle Scholar
• 73 Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid.  Arch Neurol. 2003;  60(8) 1082-1088
  CrossrefPubMedGoogle Scholar
• 74 Bolton C, Paul C. Glutamate receptors in neuroinflammatory demyelinating disease.  Mediators Inflamm. 2006;  2006(2) 93684
  PubMedGoogle Scholar
• 75 Lipton S A. NMDA receptors, glial cells, and clinical medicine.  Neuron. 2006;  50(1) 9-11
  CrossrefPubMedGoogle Scholar
• 76 Pitt D, Werner P, Raine C S. Glutamate excitotoxicity in a model of multiple sclerosis.  Nat Med. 2000;  6(1) 67-70
  PubMedGoogle Scholar
• 77 Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress.  Biomed Pharmacother. 2004;  58(1) 39-46
  CrossrefPubMedGoogle Scholar
• 78 Kauppinen T M, Suh S W, Genain C P, Swanson R A. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.  J Neurosci Res. 2005;  81(2) 190-198
  CrossrefPubMedGoogle Scholar
• 79 Ji B, Li M, Wu W T et al.. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury.  Mol Cell Neurosci. 2006;  33(3) 311-320
  CrossrefPubMedGoogle Scholar

Peter A CalabresiM.D. 

Associate Professor, Department of Neurology, Johns Hopkins School of Medicine

600 North Wolfe Street, Pathology 627, Baltimore, MD 21287

Email: calabresi@jhmi.edu